The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022 BioNTech is evaluating sustainable mRNA vaccine production ...
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on BioNTech SE’s (NASDAQ:BNTX) Investigational New Drug application (IND) and the related Phase 1/2a trial evaluating the ...
March 4 (Reuters) - The U.S. Food and Drug Administration has placed a clinical hold on BioNTech's early-to-mid stage trial of an experimental malaria vaccine, the drugmaker said in a filing, sending ...
With the added help from CEPI, BioNTech figures its Kigali plant could become the first commercial mRNA facility in Africa. (stellalevi/iStock/Getty Images Plus) As ...
Investing.com – BioNTech (NASDAQ:BNTX) stock rose more than 3% Monday following the launch of the company’s ‘Project Malaria’ which aims to develop a vaccine to prevent malaria in Africa. The vaccine ...
BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the ...
While researchers have spent decades searching for malaria vaccines, only two have ever been authorized, a situation many scientists hope to change as they race to leverage new technology against one ...
The US Food and Drug Administration has put a clinical hold on BioNTech’s investigational new drug (IND) application and Phase I/II clinical trial examining the company’s pipeline malaria vaccine. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results